Drug news
NICE rejects Pixuvri (Cell Therapeutics) for the treatment of Non-Hodgkin's Lymphoma
NICE has issued draft guidance not recommending the use of Pixuvri (pixantrone), from Cell Therapeutics, for an aggressive form of Non-Hodgkin's Lymphoma. The committee concluded there was insufficient evidence to show that the drug is more effective than current treatments and also found that it does not represent good value for money. According to NICE, the clinical trial evidence submitted "highlighted a number of uncertainties that called into question the true benefit people might receive from this treatment."
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins